HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

CONCLUSION: After tumor progression with EGFR TKI therapy and PBC in patients with EGFR-mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR-mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970).PMID:37689979 | DOI:10.1200/JCO.23.01476

Source: Clinical Lung Cancer - September 10, 2023 Category: Cancer & Oncology Authors: Helena A Yu Yasushi Goto Hidetoshi Hayashi Enriqueta Felip James Chih-Hsin Yang Martin Reck Kiyotaka Yoh Se-Hoon Lee Luis Paz-Ares Benjamin Besse Paolo Bironzo Dong-Wan Kim Melissa L Johnson Yi-Long Wu Thomas John Steven Kao Toshiyuki Kozuki Erminia Massa Source Type: research